SCHEMBL63252

SCHEMBL63252

CCOC(=O)c1nc([C@H]2CCC[C@@H](CO)O2)[nH]c(=O)c1O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.37
ERCC1 P07992 4/20 0.36
ERCC4 Q92889 4/20 0.36
KDM4E B2RXH2 6/20 0.35
ALDH1A1 P00352 5/20 0.35
HPGD P15428 4/20 0.35
GAA P10253 3/20 0.35
HSD17B10 Q99714 2/20 0.35
TSHR P16473 1/20 0.35
RNASEH1 O60930 1/20 0.35
KDM5A P29375 1/20 0.34
KDM5B Q9UGL1 1/20 0.34
MAPT P10636 2/20 0.33
POLB P06746 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
MAPK1 P28482 1/20 0.32
HTT P42858 1/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL52120 1.00 LMNA (0.37) LMNAERCC1ERCC4KDM4EALDH1A1
SCHEMBL62745 1.00 LMNA (0.37) LMNAERCC1ERCC4KDM4EALDH1A1
SCHEMBL87342 0.77 ERCC1 (0.41) LMNAERCC1ERCC4KDM4EALDH1A1
SCHEMBL62403 0.77 ERCC1 (0.41) LMNAERCC1ERCC4KDM4EALDH1A1
SCHEMBL62609 0.75 ERCC1 (0.38) LMNAERCC1ERCC4KDM4EALDH1A1
SCHEMBL86983 0.75 ERCC1 (0.38) LMNAERCC1ERCC4KDM4EALDH1A1
SCHEMBL13447864 0.67 RNASEH1 (0.52) KDM4EALDH1A1HPGDGAARNASEH1
SCHEMBL51796 0.66 ERCC1 (0.35) ERCC1ERCC4KDM4EMAPT
SCHEMBL51795 0.66 ERCC1 (0.35) ERCC1ERCC4KDM4EMAPT
SCHEMBL62529 0.66 ERCC1 (0.35) ERCC1ERCC4KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG LMNA 1838/4885ERCC1 236/4885ERCC4 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.